Headlines about Veracyte (NASDAQ:VCYT) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Veracyte earned a news impact score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.9292568098779 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Veracyte (VCYT) traded up $0.22 during trading on Thursday, reaching $6.48. The company’s stock had a trading volume of 88,600 shares, compared to its average volume of 88,791. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.59. The stock has a market cap of $213.09, a P/E ratio of -8.00 and a beta of 1.75. Veracyte has a twelve month low of $5.75 and a twelve month high of $9.80.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.21) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.21). The business had revenue of $17.50 million for the quarter, compared to the consensus estimate of $19.54 million. Veracyte had a negative return on equity of 52.99% and a negative net margin of 38.19%. The company’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.20) EPS. analysts expect that Veracyte will post -0.87 EPS for the current fiscal year.

Several brokerages recently weighed in on VCYT. Zacks Investment Research downgraded Veracyte from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. Leerink Swann dropped their target price on Veracyte from $12.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Janney Montgomery Scott downgraded Veracyte from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 7th. Piper Jaffray Companies downgraded Veracyte from an “overweight” rating to a “neutral” rating in a research note on Tuesday, November 7th. Finally, BTIG Research set a $13.00 price target on Veracyte and gave the company a “buy” rating in a research note on Monday, November 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $11.85.

In other Veracyte news, Chairman Bonnie H. Anderson sold 16,000 shares of the business’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $9.41, for a total transaction of $150,560.00. Following the sale, the chairman now owns 16,000 shares in the company, valued at approximately $150,560. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Veracyte (VCYT) Receiving Somewhat Favorable Media Coverage, Analysis Shows” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/18/veracyte-vcyt-receiving-somewhat-favorable-media-coverage-analysis-shows.html.

About Veracyte

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.